- Questions raised against India’s Covexin, Covexin is made by Bharat Biotech
- Scientists conducted the study on the vaccine between January 2022 and August 2023
- A new study on Covexin claims that one-third of people experienced side effects after one year
A new study has been done by some scientists from Banaras Hindu University. The research has been published in the journal Science. Scientists have conducted this study between January 2022 and August 2023. A total of 1,024 people were included in this. In which 635 teenagers and 291 adults were involved. These people were interviewed over the phone one year after the vaccine.
What was found in the study?
The study found that about one-third of people who took doses of Covexin developed serious side effects. Another important thing was that about 50 percent of people complained of infection. Most of the cases were respiratory infections. Among the 635 teenagers included in the study, 10.5 percent developed skin disorders. Nervous system disorders
Of the 635 adolescents in the study, 10.5 percent had skin disorders. Nervous system disorders were observed in 4.7% of adolescents and general disorders were observed in 10.2% of adolescents. Now, among the 291 adults who were part of the study, the same problems were found for teenagers.
The percentage of common disorders in adults was 8.9%. Disorders related to muscles and bones were observed in 5.8% of people and disorders related to the nervous system were observed in 5.5% of adults. Covaxin has serious side effects on women. Period-related abnormalities were observed in 4.6% of women participating in the study. Eye problems were seen in 2.7% and hypothyroidism in 0.6% of women. stroke in 0.3% and Guillain-Barré syndrome in 0.1% of participants. The short form GBS, was also identified. GBS is a rare disease that slowly causes paralysis in large parts of the body.
How many deaths have been caused by Covaxin?
Of the people who participated in the study, the researchers found that four adults also died. It includes three women and one man. All four had diabetes, of which three adults also had high blood pressure. Two out of four deaths were due to stroke.
One death was due to post-Covid gonadocerebral mucormycosis. Rhinocerebral mucormycosis is also known as zygomycosis. It is a rare and fatal disease that mainly affects the nose, paranasal sinuses and brain. The fourth death was of a woman who fainted several times after vaccination. However, the cause of his fainting is not known. The study reported that the risk of AESI was four times greater in adults who received three doses of Covexin compared to adults who received two doses.
What the biotech company clarified
The Bharat Biotech company said after the research came out that it has seen good safety results in several studies of the Covid-19 vaccine, Covexin. This has also been published in many major journals. The company said in its statement that due to security reasons, some data is needed to avoid any bias in order to complete the impact of this type of study. The company said that research shows that. Nor, what was the AESL profile of people prior to participating in the study? This type of data was not included in BAU’s research.
How much research should be feared?
According to an infectious disease specialist, 90 percent of the people who have been vaccinated in India have taken CoviShield and about 9.5 percent have had Covaccine and the rest have taken another company’s vaccine. They say that the best thing about this study is that this BHU said that but its biggest flaw is that it did not compare the population. If 1000 people were studied in this research, then 1000 people who have received the vaccine should have been included. Those who were not vaccinated. The study should compare the safety profile of non-vaccinated subjects with the safety profile of people who received another vaccine.
Finally, according to an infectious disease specialist Tabi, it is believed that research has been published in the journal Science. Which is a German British company. The AstraZeneca CoviShield vaccine was manufactured by a German company. When the CoviShield scandal broke, it was published in an effort to fast track it so that the public could get the word out that Covaccine was not safe.
What is Covishield’s ultimate controversy?
British pharma company AstraZeneca has admitted in court that its Covid-19 vaccine can cause serious side effects. The vaccine was also withdrawn a few days ago. We know this vaccine as Covishield in India. AstraZeneca developed the vaccine in collaboration with the University of Oxford and sent it to India in partnership with the Serum Institute. Death after vaccination. AstraZeneca is facing legal action over blood clots and other problems. Several families alleged that the vaccine had caused serious side effects.
